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Abstract 
Silk is an important biopolymer for (bio)medical applications because of its unique and 
highly versatile structure and its robust clinical track record in human medicine. Silk can 
be processed into many material formats, including physically and chemically cross-
linked hydrogels that have almost limitless applications ranging from tissue engineering 
to biomedical imaging and sensing. This concise review provides a detailed background 
of silk hydrogels, including silk structure-function relationships, biocompatibility and 
biodegradation, and it explores recent developments in silk hydrogel utilization, with 
specific reference to drug and cell delivery. We address common pitfalls and 
misconceptions while identifying emerging opportunities, including 3D printing.  
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Introduction 
Silk has a unique and highly versatile biopolymer structure that makes it ideal for 
biomedical applications. It is particularly useful for cell and drug delivery, because it can 
be processed into many material formats, including fibres, fabrics, films, scaffolds, 
hydrogels and micro- and nanoparticles [1]. Furthermore, this high-performance 
biomaterial is already FDA/EMA/MRHA clinically approved (for load bearing 
applications), and has renowned biocompatibility, tuneable biodegradation (minutes to 12 
months and more) and low immunogenicity [2]. Its unique physical properties (e.g. 
toughness) have long supported its use as a suture material (e.g. Ethicon, Inc.) and more 
recently as a surgical mesh for load-bearing applications (Allergan, Inc.) [3]. In China, 
the Sidaiyi¨ wound dressing (i.e. a silk sponge attached to a silicon film) is licensed for 
human use in donor site partial- and full-thickness wounds, donor site wounds and burns. 
Further expansion of silk use is evident in ongoing clinical proof-of-concept studies 
available in the public domain: (i) silk-based meshes for breast reconstructive surgery [4] 
and (ii) silk films as a wound dressing [5]. Commencement of a Phase I clinical study 
using silk coatings of silicone breast implants for improved host-tissue response 
(BioShield-S1, AMSilk GmbH Germany) is expected shortly.  
 
 Overall, silk has a robust safety record, making it a highly attractive material for 
state-of-the-art medical applications, including stimulus-responsive nanomedicines, 
payload stabilisation (drugs, proteins and diagnostics; developed by Vaxess Inc., MA, 
USA), medical sensors, hydrogels for drug and cell delivery, tissue engineering and in 
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vitro disease modelling. This review does not attempt to provide a comprehensive review 
of all silk hydrogels proposed for drug and cell delivery/tissue engineering nor does it 
assess in detail the manufacturing techniques used (these have been reviewed elsewhere; 
e.g. [6]). Instead, the aim of this review is to deliver a critical assessment of the current 
opportunities and challenges of silk hydrogels and to provide a wider context for their 
use. 
 
Silks 
In this review, the term silk refers to protein-based fibre-forming materials spun by living 
organisms. Spiders and silkworms are the most prominent organisms associated with silk 
production, although silks are made by many other organisms [7, 8]. This review will 
critically examine the literature related to Bombyx mori silk. 
B. mori is the domesticated silkworm that is exploited for commercial sericulture (i.e. silk 
farming). For the purpose of this review, we will focus on silkworm silk (Fig. 1) because 
this is the most common silk used in ongoing biomedical research due to its ready 
availability and it is currently in clinical use in humans for load-bearing applications [1].  
 
Bombyx mori silk 
The exact molecular size of silk varies among different B. mori strains due to variations 
in the lengths of the crystalline coding domains in the silk heavy chain [10]; therefore, the 
reported variations in molecular weight are potentially due to biological variability and/or 
differences in experimental approaches. The B. mori silk consists of a heavy chain 
(approximately 391 kDa) [11, 12] and a light chain (approximately 26 kDa) [13], which 
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are held together by a single disulphide bond at the C-terminus [14] (Fig. 1b). The 
mechanical properties of silk arise from the unique amphiphilic protein structure of its 
heavy chain, which includes 11 short hydrophilic regions that are typically 31 amino 
acids long, together with hydrophilic C- and N-terminal capping sequences consisting of 
completely non-repeating amino acid residues (Fig. 1). The 11 hydrophilic regions are 
interspaced within the heavy chain, which consists of 12 hydrophobic blocks that account 
for 94% of the heavy chain sequence [11]. These hydrophobic blocks contain highly 
repetitive glycine-X (GX) repeats, where X is alanine (A) (65%), serine (S) (23%) or 
tyrosine (Y) (9%) [11]. The exact composition of these hydrophobic regions depends in 
part on their position in the silk heavy chain.#167} 
 
 The GX hydrophobic blocks can be classified into three motifs: (i) a highly 
repetitive GAGAGS sequence that makes up the bulk of the crystalline regions and is 
typically found at the start of each block; (ii) a less repetitive sequence, containing 
hydrophobic and/or aromatic residues GAGAGY, GAGAGV and GAGAGVGY, that 
forms the semicrystalline regions; and (iii) sequences very similar to (i) except for the 
presence of an AAS motif, which is usually found at the C-terminal end of each 
subdomain and may form a sheet-breaking motif (Fig. 1b,c) [15, 16]. Apart from having a 
fibroblast growth-promoting peptide at the N-terminal region of the silk heavy chain [17], 
B. mori silk lacks the RGD sequence necessary for integrin-mediated cell attachment.  
 
 Overall, the silk heavy chain is of particular importance when designing 
physically crosslinked silk hydrogels for cell and drug delivery, as it is responsible for 
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hydrogel performance. This is because the crystalline regions form physical crosslinks, 
while the amorphous regions provide network flexibility. These discrete functional 
domains arise due to the block copolymer arrangement of silk and its ability to adopt a 
defined secondary structure (for example [16]). Additional chemical crosslinking of silk 
hydrogels can occur via the reactive amino acids found in the silk (heavy) chain (i.e. the 
number of these residues are: serine 635, tyrosine 277, threonine 47, glutamic acid 30 and 
aspartic acid 25) [18]. Therefore, targeting of specific locations within the silk structure is 
possible because the amino acid sequence of silk is known. For example, serine residues 
are predominately located within the crystalline domains, while tyrosines are typically 
found in the non-crystalline domains. The reactive amino acids present in the silk light 
chain could also be exploited for chemical crosslinking [18]; however, the reverse 
engineering processes used with the silk cocoons often damage the disulphide linkage 
between the heavy and light silk chains (detailed below). Therefore, chemistries that 
target the more robust silk heavy chain are preferred. 
 
 The silk primary structure can assume various forms, including random coils, β-
sheets, α-helices and turns. The hydrophobic domains can form crystalline anti-parallel β-
sheets joined by hydrogen bonds; these give silk its mechanical strength, while the 
abundance of these secondary structures determines its stability and mechanical 
properties [8, 15]. The formation of the silk secondary structure can be controlled by 
varying processing conditions, such as water removal, stretching and ions.  
 
 One critical consideration in silk chemistry is that the primary structure of native 
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silk cannot be faithfully reproduced or engineered via synthetic approaches. The huge 
protein structure and the high glycine content (45.9% glycine) [11] preclude the use of 
standard biotechnological approaches to manufacture native B. mori silk.  
 
 At its high concentration (up to 35% w/v) within the silk gland, silk adopts a 
spherical micelle conformation (100 to 200 nm in diameter), consisting of a hydrophobic 
core and a hydrophilic shell formed by the N- and C-terminal domains [19] (Fig. 1a). The 
N-terminal domain is pH responsive, so that a drop in pH in the anterior part of the silk 
gland results in protonation of the acidic side chains. This, in turn, promotes hydrogen 
bonding and the transition of silk I (random coils, helices and hydrated β-strands) to a 
silk II conformation (i.e. β-sheets). One potential scenario includes a stabilisation of the 
silk gel state by pH-induced hydrogen bonding through aggregation of the spherical 
micelles [20]. The micelles subsequently elongate and align in response to shear forces 
during the spinning process and the spun silk thread emerges from the head of the silk 
worm. During the spinning process, the β-sheet crystals are preferentially aligned parallel 
to the fibre axis [20]. These β-sheet crystals are distributed within the amorphous silk 
matrix but are able to interlock because of partial twisting of the nanofibrils. The 
interlocking minimises slippage and inhibits crack propagation when a load is applied 
[21]. Thus, the hierarchal structure of silk, from its unique amino acid composition to its 
assembly, is responsible for the overall mechanical properties of this biopolymer.  
  
Reverse engineering the silk cocoon 
In the early 1930s the traditional silk processing methodologies were refined and first 
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reports emerged for the use of Na2CO3 for degumming [22] (i.e. removing sericin and 
waxes, detailed below) and LiBr [23] to solubelise the silk fibre (Fig. 2). The ability of 
silkworms to synthesise and store liquid silk has subsequently inspired David Kaplan 
(Tufts University, MA, USA) and co-workers to use these top-down approach to fully 
reverse engineered silk cocoons for biomedical applications. An aqueous B. mori silk 
solution is typically used to generate novel silk formats, including (self-assembling) silk 
hydrogels. The processing parameters selected for reverse engineering have a direct 
impact on the resulting silk. A key goal of silk processing is the complete removal of 
sericin, because sericin is a known inducer of inflammatory responses [2, 24]. Sericin 
also acts as a ÒglueÓ, and emerging evidence suggests that it also inhibits the premature 
conversion of soluble silk (silk I) into gelated and β-sheet silk conformations [25].  
 
 The first step in reverse engineering a silk cocoon is to cut it into small pieces 
[26]; this contrasts starkly with the treatment of silk for textile applications, where the 
intact silk thread is required. The silk pieces are then ÒdegummedÓ by enzymatic methods 
(i.e. digestion of sericin but not silk) or chemical processing (e.g. alkaline treatment, most 
typically Na2CO3) to remove sericin. Chemical processing with sodium carbonate is the 
most common method and typically involves boiling for 20 to 60 minutes (i.e. the 
degumming time). Complete sericin removal can be achieved within 5 minutes, but this 
prolonged degumming (>5 minutes) process damages the silk structure, and especially 
the disulphide linkage between the silk light and heavy chain, as well as the amorphous 
regions within the silk heavy chain [27]. This damage is seen as an increase in silk 
polydispersity, a reduction in silk solution conformation from 100  (for native silk) to 
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25  (measured by small angle neutron scattering) [28] and changes in rheological 
properties [29]. Boiling times are often empirically selected, but prolonged degumming 
will ultimately yield a silk solution that takes longer to aggregate (and thus has a longer 
shelf life) and is easily filter-sterilised due to reduced viscosity. Optimum degumming 
times have ranged from 20 minutes for the manufacture of silk scaffolds to more than 60 
min for the production of nanoparticles [30]. However, extensive degumming (>60 
minutes) is expected to adversely affect silk self-assembly, which in turn is detrimental to 
the formation of physically crosslinked silk hydrogels (i.e. the time for the solutionÐgel 
transition is prolonged). Therefore, most studies reported in literature use degumming 
times of 20 to 60 minutes to create silk stocks (which are then fully reverse engineered, 
as detailed below).  
 
 Following degumming, the pure silk fibres are dried and subsequently dissolved 
in a chaotropic agent (e.g. lithium bromide, urea, etc.) [26]. For example, silk fibres are 
dissolved in LiBr (e.g. 9.3 M) at 60¡C for up to 4 hours to dissemble the silk secondary 
and tertiary structure. The resulting viscous solution is then extensively dialysed against 
water to yield an aqueous silk solution (typically 7% w/v). Higher silk concentrations 
(e.g. 20% w/v) can be achieved by dialysing the silk solution against polyethylene glycol 
to extract water (note that prolonged dialysis will lead to the formation of a silk 
hydrogel). During the reverse engineering, the silk does not aggregate and the resulting 
silk solution is stable at 4¡C for several months. (Note that silk concentrations higher than 
8% w/v will aggregate more easily) (Fig. 2).  The reverse engineered silk solution can be 
used to generate many different silk formats (e.g. films, fibres, scaffolds, (nano)particles, 
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etc.) [1, 30], including silk hydrogels for drug and cell delivery.  
 
Delivery of therapeutic payloads Ð key considerations 
During the early stages of drug development, the use of the active pharmaceutical 
ingredient (i.e. the drug) to study the mechanism of drug action is often sufficient. 
However, moving a promising active pharmaceutical ingredient into animal models, and 
ultimately into man, typically requires the ÒformulationÓ of the drug into a medicineÑa 
key mission of pharmaceutical sciences. To complete its journey from bench to bedside, a 
drug must be evaluated for a number of factors; for example, the most appropriate route 
of administration (e.g. oral, parenteral, transdermal, subcutaneous, ocular, intra-articular 
etc.) with the view of using a ÒlocalÓ or ÒsystemicÓ treatment strategy.  
 
 In the context of cancer, targeting a systemically administered drug therapy to the 
tumour site using a macromolecular carrier approach is desirable, as this will (i) reduce 
side effects, (ii) increase drug concentrations at the target site and (iii) ultimately 
modulate the pharmacokinetic characteristics, independent of the physicochemical 
properties of the therapeutic payload. A macromolecular carrier approach also has the 
potential to overcome drug resistance mechanisms (e.g. efflux pumps in the plasma 
membrane) (e.g. [31]). This is because the cell entry mechanisms for a small molecular 
payload can be changed from passive diffusion across the plasma membrane (i.e. 
governed by the physicochemical properties of the drug) to a carrier-mediated endocytic 
uptake mechanism (i.e. uptake governed by the design of the macromolecule and not the 
payload) (e.g. [31]). Already, today, a number of macromolecular carrier approaches are 
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being used in the clinic to deliver small molecular weight anticancer drugs [32], while 
silk-based systems (i.e. nanoparticles) are in early pre-clinical development [30].  
 
 Alternatively, focal (i.e. local) cancer therapy is used clinically for cancer therapy 
(reviewed in [33, 34]). Examples include intravesical therapy for bladder cancer, hepatic 
arterial infusion therapy for hepatocellular carcinoma, brachytherapy of early stage breast 
cancer and delivery of carmustine by controlled-release polymeric wafers (Gliadel 
wafers) for the post-resection treatment of high-grade malignant glioma and recurrent 
glioblastoma multiforme. Anticancer drug delivery systems based on silk films [35-37], 
foams [38] and self-assembling silk hydrogels [38, 39] are currently showing 
encouraging results in preclinical animal models of breast cancer and neuroblastoma [33].  
 
 Irrespective of the choice of ÒlocalÓ or ÒsystemicÓ delivery, the therapeutic 
payload must be sufficiently stable to withstand the conditions of the intended route of 
administration. For example, orally administered proteins are typically broken down due 
to the low pH in the stomach and the presence of proteolytic enzymes in the GI tract; 
thus, protein drugs are not suitable for an oral route. Furthermore, the delivery 
system/payload must have the ability to cross biological barriers encountered during 
administration. The most commonly cited barriers to drug delivery include the 
gastrointestinal tract, blood-brain barrier and intact skin; although the extent and barrier 
function various across these system. In deed many more drug delivery barriers exist. For 
example, macromolecular carriers designed for intracellular activation typically end up in 
the acidic environment of lysosomes, so their payloads need to be compatible with low 
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pH. Payloads accumulating in specific intracellular organelles (e.g. lysosomes) also 
require the ability to escape and reach their intended site of action (e.g. weakly basic 
drugs get trapped in lysosomes due to protonation in the acidic environment of the 
lysosomes, while endosomal/lysosomal escape of genetic material is hindered by the 
barrier function of the organelle membrane).  
 
Only molecules that meet a specific set of physicochemical properties are able to 
cross these biological barriers, and many drug candidates fail to meet these criteria. The 
design of a drug carrier system therefore has to facilitate the delivery of these drugs. For 
example, with transdermal patch technology, a set of well-known molecular 
characteristics of the payload are required for successful drug delivery across the skin. By 
contrast, transiently breaching the barrier function of the skin with microneedles enables 
the delivery of a much wider spectrum of drugs that, classically, have not been suitable 
candidates for transdermal delivery. This drug delivery challenge is now being met with a 
broad range of materials for microneedle design, including silk-based microneedles that 
are currently in pre-clinical development [40].  
 
 While the concepts for delivery active pharmaceutical ingredients are well 
established, the delivery of living cells as therapies is more challenging because of the 
need to ensure that the cells maintain their viability and are able to perform their intended 
functions. Therefore, intense efforts by the tissue engineering community are ongoing to 
deliver cells and to ensure that the delivered cells can augment or even regenerate the 
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target tissues (reviewed [41]). In this context, silk has emerged as a useful biopolymer for 
the delivery of cell-based therapeutics. 
 
Rationale for using silk for drug and cell delivery 
The attributes of silk typically cited for its use for cell and drug delivery, include (i) 
biocompatibility, (ii) biodegradability, (iii) mild processing conditions, (iv) protection of 
the payload and (v) approved use in humans. However, the generic use of the term 
ÒbiocompatibilityÓ to describe all silks is potentially misleading. First, clinical experience 
with silk in humans is limited to B. mori silk-based films for wound healing (although 
with limited public accessible data) and its use as sutures and surgical meshes (a strong 
track record exists for these latter two). Therefore, novel applications of silk still require 
careful assessment to ensure patient safety, and this is of particular importance when 
novel silk formats are being proposed for applications that go beyond current load-
bearing applications and topical placement on the skin.  
 
 The concept that a material needs to be Òfit for its intended purposeÓ is well 
established [42], and greater rigor is needed by the scientific community to ensure that 
silk is not simply labelled as ÒbiocompatibleÓ without supporting evidence for the 
ultimate intended use.  
 
Silk hydrogel biocompatibility and biodegradation 
Adverse reactions reported for silk (sutures and surgical meshes) in man can be largely 
attributed to contaminating sericin, as this causes an allergic reaction [24]. Like all non-
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autologous materials, silk elicits a foreign body response following implantation in vivo, 
but this response is comparable to that induced by the most popular synthetic materials in 
use today [e.g. poly(lactic-co-glycolic acid), polycaprolactone, polylactic acid etc.] [2].  
 
 The two most prominent biocompatibility studies for silk films [43] and scaffolds 
[44] are often cited as evidence that silk hydrogels are also biocompatible. This is not 
scientifically rigorous evidence, because the material format, silk processing, 
implantation site and amount of material transplanted, as well as the animal model used, 
will all influence biological performance. Therefore, application-oriented 
biocompatibility studies are important. For example, Michael House (Tufts Medical 
Center, Boston, MA, USA) and co-workers are making the first inroads into assessing the 
biocompatibility of silk hydrogels in pregnant rats as a potential therapeutic strategy to 
prevent preterm birth [45]. Here, sonication-induced silk hydrogels were filled into 
syringes and injected into the cervixes of pregnant rats (gestational day 13) before the 
hydrogel had completed the solutionÐgel transition. Histological assessment of the tissue 
response at gestational day 17 showed a mild foreign body response similar to that 
observed with polyglycollic acid and poly(ethylene terephthalate) sutures [45]. This 
short-term in vivo biocompatibility study was supplemented by in vitro studies with 
human cervical cells, which showed no up-regulation of inflammatory markers [45]. 
However, the longer-term effects, such as longitudinal inflammatory responses, 
biodegradation or impacts on pregnancy (e.g. a shift in the delivery date), are currently 
unknown.  
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One longer-term study (3 months) compared sonication-induced silk hydrogels 
and collagen type I hydrogels both in vitro and in vivo [46]. Nude mice, at one and two 
weeks post implantation of silk hydrogels, showed a local inflammatory response but this 
was substantially less than the response observed with collagen hydrogels. Both the 
collagen and the silk material attracted neutrophils, eosinophils and macrophages, but 
these immune cells infiltrated the collagen hydrogel material and subsequently degraded 
the hydrogel completely within 4 weeks. By contrast, the silk hydrogels showed no 
infiltration by these cells at 1 or 2 weeks. At week 4, the inflammation around the silk 
hydrogel was greatly reduced and the hydrogel had cracks that were populated by spindle 
shaped cells. At 3 months, no inflammatory cells could be detected in or around the silk 
hydrogels, but vascularisation was apparent and the spaces in the hydrogel cracks were 
populated by stromal cells [46]. The use of athymic mice (in the absence of transplanting 
xenogenic cells) to assess biocompatibility is surprising due to the lack of the adaptive 
immune system (although this is typically not activated by silk).  
 
 In rats, subcutaneously implanted 8% w/v silk hydrogels showed significant 
hydrogel remodelling at 15 weeks post implantation, resulting in vascularisation and loss 
of the hydrogel shape [47]. The performance of sonication-induced silk hydrogels was 
also assessed in healthy brains of adult mice [48]. Silk undergoing the solutionÐgel 
transition was stereotaxically injected into the caudate putamen (striatum) and subsequent 
silk performance was examined using a battery of histological, electrophysiological and 
behavioural assessments. Flow cytometry of CD45 positive (immune) cells showed a 
significant increase at 72 hours post silk injection, but the numbers declined at 2 weeks to 
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levels comparable to a physiological saline control group. At 4 weeks, the silk or 
physiological saline injected animals had equivalent numbers of CD45 positive cells 
when compared with healthy controls [48].   
 
 Preliminary studies in healthy rabbits indicated that intravitreal injection of 
sonication-induced 2% w/v silk hydrogels resulted in a similar acute response at early 
time points when compared with a vehicle control. At day 30, the silk-treated animals 
showed a mild inflammation, primarily in the anterior portion of the eye, cornea and 
vitreous. This response, especially in the vitreous, appeared to be transient and was less 
frequent and severe at the end point of the study (day 90) [49]. Overall, dedicated 
biocompatibility studies for silk hydrogels are scarce, but the available data are 
encouraging [45-49]. 
 
 The US Pharmacopeia classifies silk (sutures) as non-resorbable. However, this is 
based on the definition that the material Òloses most of its tensile strength within 60 daysÓ 
post-implantation in vivo. Silk sutures significantly degrade within 1 year, and they are 
completely resorbed within 2 years [24]. Similar observations have been made for silk 
surgical meshes. While substantial data exists for the biodegradation of silk films and 
scaffolds in vivo, only a few studies relate to silk hydrogels. For example, Etienne and co-
workers used sonication-induced hydrogels that were preformed ex vivo using a 4% w/v 
silk solution (40 minute degummed) [46]. Cylindrically shaped 8 × 6 mm silk hydrogels 
were then implanted subcutaneously in Swiss nude mice and the biological response 
assessed over 3 months by histology [46]. At the end point of this study, fragmentation of 
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the silk hydrogel was reported, although the hydrogel maintained its shape and showed 
signs of vascularisation [46]. However, the exact extent of silk hydrogel degradation was 
not assessed, nor was the mechanism of vascularisation.  
 
 Silk hydrogels (8% w/v) implanted into the hind limb thigh of adult rats showed a 
time dependent increase in hydrogel pore size and vascularisation over 18 weeks, which 
was attributed to silk degradation and remodelling [50]. Preliminary studies have 
assessed the biodegradation of sonication-induced silk hydrogels in healthy brains of 
adult mice [48]. Based on histological assessment, the 2% w/v silk hydrogel showed a 
volume reduction of approximately 50%, which was attributed to silk hydrogel 
biodegradation [48]. (Note, however, that other scenarios are possible, such as hydrogel 
or tissue contraction).  
 
 In vitro studies and mapping of the silk primary sequence to known protease 
cleavage sites indicates that proteases (e.g. α-chymotrypsin, collagenase) and matrix 
metalloproteinases (MMPs; MMP-1, MMP-2, interstitial collagenase and gelatinase A) 
are particularly active in silk degradation [51]. Silk is biodegradable due to its 
susceptibility to (serine/cysteine) proteases (e.g. matrix metalloproteinases, collagenase 
and α-chymotrypsin) and enzyme-catalysed hydrolysis reactions (Fig. 3). In particular, 
the disulphide bond between the light and heavy chains, as well as the amorphous silk 
sequences, are highly susceptible to degradation. By contrast, the crystalline regions in 
the silk heavy chain are substantially more resistant to proteolytic degradation due to 
reduced chain flexibility and access. Therefore, the β-sheet content has a protective effect 
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on silk degradation both in vitro [24, 43, 51-53] and in vivo [43, 44]. The packing 
geometries also show differences within the crystalline regions, ranging from tight to 
looser chain packing. The more loosely packed crystalline regions are particularly more 
susceptible to degradation and are degraded first [53]. Experience with silk films and 
scaffolds have indicated that the scaffolds degrade faster, most likely due to their 
increased surface area to mass ratio for proteolytic attack when compared to a monolithic 
film. One might therefore speculate that silk hydrogels would degrade even faster than 
silk scaffolds.  
 
 Silk sequence alignment indicates 434 and 81 α-chymotrypsin cleavage sites in 
the silk heavy chain and light chain, respectively, and 348 and 41 protease XIV cleavage 
sites, respectively (Fig. 3) [9]. Perhaps counterintuitively, this suggests that α-
chymotrypsin degrades silk significantly faster than protease XIV. However, 
experimental evidence clear indicate that protease XIV leads to faster silk hydrogel 
degradation than α-chymotrypsin  [51]; similar observations have been reported for other 
material formats, including silk nanoparticles [9]. Thus, the differences in silk 
degradation are not governed only by the number of cleavage sites but also depend on 
enzyme accessibility, the silk format and the secondary structure of the silk.  
 
 Protease XIV is a useful proteolytic model enzyme for uncovering some of the 
fundamentals of silk degradation over short study intervals (e.g. hours to days). Protease 
XIV first digests the more loosely packed β-sheets (rather than the densely packed ones). 
However, protease XIV is a non-mammalian enzyme and thus of limited relevance when 
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assessing silk degradation in the biomedical context. Furthermore, protease XIV 
degradation products yielded both soluble products and nanofibrils (4 nm thick and 80Ð
100 nm long) that reduced cell viability (IC50 75 µg/ml), whereas α-chymotrypsin 
degradation products were not cytotoxic at the tested concentrations (IC50 > 225 µg/ml) 
[53]. Overall, these findings emphasise the need to select and apply the most appropriate 
biocompatibility testing to yield meaningful results.  
 
The challenges with silk 
Silk has many advantages over other (bio)polymers, but it also has limitations. For 
example, the exact molecular size of silk varies across different B. mori strains [10]. It is 
therefore important to work with a reliable silk supply chain to ensure product 
consistency. 
 
B. mori silk is a natural product and thus highly responsive to its environmental 
conditions during sericulture. This necessitates the supply of high-quality mulberry 
leaves, performance of pest control monitoring and maintenance of optimum rearing 
conditions. For example, humidity during silk cocoon spinning impacts the final product. 
Silk spun in a low-humidity environment shows a low crystallinity due to the limited 
availability of water vapour for post-spun silk annealing [54]. Humidity can thus impact 
the mechanical properties of silk. Nonetheless, a potential advantage of silk cocoons spun 
at low humidity is that the silk can be physically extracted from sericin [54]. This 
eliminates the need to boil the silk, which can damage its primary structure and increases 
the biopolymerÕs polydispersity. 
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Silk hydrogel studies typically use a polydispersed, reverse-engineered silk 
solution. However, this complicates comparisons across different studies and makes it 
more challenging to implement quality control measures and, ultimately, clinical 
translations. A reverse-engineered silk solution has a limited shelf life because the silk 
will eventually self-assemble, which necessitates the constant supply of fresh silk. 
Reverse engineering silk is a batch process and difficult to fully automate. This is a 
challenge for the pharmaceutical industry, where current manufacturing paradigms are 
shifting to a continuous production process with minimal manual labour. 
 
Although silk has a long track record of human use, adverse reactions to virgin 
silk sutures have demonstrated that complete sericin removal is critical to achieving 
biocompatibility in patients [24]. Therefore, appropriate fibre processing is a crucial step 
to generating hypoallergenic silks. Silk-based medical devices approved for human use 
demonstrate that it is possible to navigate these challenges and generate silk that complies 
with Good Manufacturing Practices and licensing requirements. 
 
Silk hydrogels for drug and cell delivery 
In the context of drug delivery, silk hydrogels are exploited for their ability to trap, retain, 
protect and deliver therapeutics payloads. The selection of the silk processing parameters 
(e.g. the amount of silk) and the inclusion of silk hydrogel modification(s) (e.g. drug 
loaded silk particles, chemical modification of silk, etc.) impact the overall performance. 
Furthermore, the selection of the payload (e.g. small molecular weight drug, therapeutic 
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protein, etc.) and the subsequent environment the silk hydrogel encounters (e.g. vitreous 
of the eye, tumour microenvironment, etc.) will determine its overall performance (e.g. 
drug release, biocompatibility, biodegradation etc.). Unlike silk hydrogels used for drug 
delivery, those used for cell delivery typically serve as a (orphan) cell niche. Therefore 
fine tuning strategies (e.g. elastic modulus, chemical functional groups, etc.) applied to 
silk hydrogels typically aim to recapitulate the extracellular matrix (ECM). The ECM, in 
turn, orchestrates numerous functions, which include (but are not limited to) (stem) cell 
quiescence, migration, proliferation, self-renewal and differentiation [55]. Thus silk 
hydrogel modification opens up new possibilities to endow silk with novel functions, 
including its ability to serve as an ECM mimetic.  
 
Silk lacks integrin binding domains, but the presence of chemically reactive 
groups at known sites within the silk molecule enables its precise functionalisation at 
predefined locations [18]. However, unmodified silk hydrogels have also been 
successfully used for cell culture probably due to the adsorption of serum proteins (e.g. 
fibronectin) and to the production of endogenous ECM by the cells themselves. 
Irrespective of their intended use, self-assembling silk hydrogels have excellent 
injectability due to shear thinning, they show minimal swelling during the solutionÐgel 
transition and they typically have good biocompatibility.  
 
Self-healing hydrogels are emerging as useful materials for biomedical 
applications. However, self-assembling silk hydrogels form strong physical cross-linked 
networks that are not self-healing. Applying the basic principles of dynamic ligand-
 22 
mediated self-assembly has therefore resulted in the first generation of chemically 
modified self-healing silks [56]. Furthermore, generating chimeric silks and alloys can 
endow the resulting materials with novel properties by exploiting recombinant protein 
technologies to copy nature [57]. 
 
Silk hydrogels can be broadly classified into physically [58] and chemically 
crosslinked systems [59]. For the purpose of this critical analysis, only selected silk 
hydrogel systems are discussed because others are comprehensively collated in the silk 
hydrogel literature (for example, [6, 60]).  
 
 
Physically crosslinked silk hydrogels 
Physically crosslinked silk hydrogels are particularly promising for drug delivery, tissue 
engineering and biomedical applications because their formation does not rely on 
chemical crosslinking. Therefore, fabrication avoids the use of potentially harmful agents 
such chemical initiators, crosslinkers or UV irradiation. Residual chemicals can leach 
from chemically crosslinked hydrogels, while UV-based polymerisation techniques are 
typically incompatible with cell viability or biopharmaceuticals. By contrast, self-
assembling silk hydrogels are particularly well suited for biopharmaceuticals and cell 
delivery because the payload can be added after the silk treatment but prior to the onset of 
gelation [1].  
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 A number of strategies have been explored to generate physically crosslinked silk 
hydrogels: (i) vortexing [61], (ii) ultrasound [44], (iii) temperature [62], (iv) osmotic 
stress [62, 63], (v) pH [58], (vi) CO2 acidification [64], (vii) non-solvent induced phase 
separation [65], (viii) electrical fields [66, 67] and (viii) polymers [68]. The basis for all 
these hydrogels is the self-assembling behaviour of silk due to the physical entanglements 
and hydrogen bonding between hydrophobic domains of the silk block copolymer. For 
many silk hydrogels, a change in secondary structure occurs that typically includes the 
formation of β-sheets due to water exclusion [69]. This is exemplified by the addition of 
highly hydrophilic polyethylene glycol (e.g. PEG300, PEG400), which binds water and 
results in excluded volume effects [68]. The resulting β-sheets give rise to strong 
intermolecular interactions and stabilise the silk hydrogel network, making the hydrogel 
structure essentially irreversible [69].  
 
 Above the critical micelle concentration, silk changes from a random coil to a 
micellar conformation [28]; in the B. mori silk gland, the high-concentration silk is in a 
gel-like state. These silk I structures are metastable and undergo weak hydrogen bonding, 
as well as hydrophobic and electrostatic interactions [69, 70]. Experimental work with 
reverse engineered silk confirms the importance of the solution concentration on silk 
hydrogel self-assembly and structure [70]. Hydrogels derived from low (1% w/v) and 
high (20% w/v) concentration reverse-engineered silk solutions showed micellar and 
fibrillar silk II structures, respectively. Importantly, at high concentrations, fibrillar 
networks were observed rather than aggregated large globules. Overall, both 
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thermodynamics and kinetic components come into play in regulating molecular 
mobility, hydrophobic/hydrophilic interactions and charge [70].  
 
Mechanistic studies with silk model peptides (GS6: GAGAGS; GS10: 
GAGAGSGAAS; GY8: GAGAGVGY; GY6: GAGAGY) [71] have provided sequence-
specific insights. For example, self-assembly behaviour was dependent on modular 
motifs, amino acid compositions and concentrations. All peptides, with the exception of 
GY6, undergo self-assembly, despite differences in secondary structure and concentration 
dependence. At high concentrations, GS6 and GS10 self-assembled to form disordered 
aggregates (random coil) to nanofibrils (antiparallel β-sheet), whereas GY8 self-
assembled into forms ranging from disordered aggregates (random coil) to small 
nanolayer-like structures (antiparallel β-sheet). At relatively low concentrations, GS6, 
GS10 and GY8 showed protofilament features. The transition times for the establishment 
of secondary structure and morphology revealed that the motifs responsible for β-sheet 
formation were GS6 > GS10 > GY8 > GY6 [71]. Silk self-assembly has inspired the 
design of synthetic self-assembling peptides [72-74] and proteins to generate Ôsilk-
mimeticÕ hydrogels (reviewed in [75]). 
 
Reverse engineered silk will eventually form a hydrogel during storage (Fig. 4), but 
shearing of the solution (i.e. by vortexing, sonication, etc.) speeds up the self-assembling 
kinetics so that silk hydrogels form within minutes to hours (note that excessive energy 
input leads to fragmentation of the silk molecule and negatively impacts hydrogel 
formation [76]). These shear-induced hydrogels transition from a silk I conformation to a 
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β-sheet dominated silk II that contains some inter-chain physical crosslinks [44]. The 
solutionÐgel transition kinetics can be further expedited by increasing the silk 
concentration, solution temperature, concentration of K+ ions, acidity (i.e. low pH) and 
energy input, and many of these factors are exploited by selecting a specific 
manufacturing protocol. For example, pH can be used as a solutionÐgel transition trigger. 
A reduction in the solution pH to a value close to the silk isoelectric point (pH 4.2) leads 
to the rapid formation of hydrogels with extensive β-sheets [58].  
 
 The responsiveness of silk to pH is governed by its amphiphilic nature and its pH 
responsive termini (which enable silk to self-assemble as it progresses along the pH 
gradient of the silk gland). The N-terminus of the silk heavy chain is acidic (isoelectric 
point 4.6) and the C-terminus is basic (isoelectric point 10.5), whereas the C-terminus of 
the light chain is acidic (isoelectric point 5.1) [60]. The acidic groups become protonated 
at low pH, leading to a reduced charge-charge repulsion that subsequently allows silk to 
adopt a more ordered state, with the formation of β-sheets that exclude water [77]. 
Another way to activate a pH-mediated trigger is to use high pressure CO2 during silk 
hydrogel manufacture. At high pressure, CO2 generates carbonic acid, which acidifies the 
silk solution, changes the hydration shell and reduces volume states of silk. This methods 
drives gelation within 2 hours, yielding silk hydrogels that are at least 2-fold more 
mechanically robust than hydrogels generated using traditional pH approaches [64].  
 
A very different silk hydrogel is formed in response to low electrical DC fields 
(typically referred to as e-gels) (Fig. 4). E-gels deposit on the positive electrode and 
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hydrogel formation is completed within minutes [66]. The electrogelation process is 
based on local pH changes that occur due to water electrolysis. The local pH drops at the 
positive electrode to a value below the isoelectric point of silk, thereby enabling silk 
deposition on the electrode, [67, 78] as predicted by ion electrodiffusion [78]. Although 
pH is also the key driver for the self-assembly of e-gels, their structure and properties 
differ markedly from other pH induced silk hydrogels. 
 
Analysis of the secondary structure of e-gels showed a transition from a random 
coil conformation to a helical conformation, but no changes in β-sheet content (as 
typically seen for other silk hydrogels). Reversal of the electric field led to a dissociation 
of the silk hydrogel and its subsequent formation at the new positive electrode; this 
process could undergo many repeat cycles [66]. These hydrogels were formed from 
nanometre-sized, metastable silk micelles [67]. In the presence of a weak electric field, 
these silk micelles formed larger spherical structures that ranged in size from nanometres 
to several micrometres. These particles were able to assemble into hydrogels because of 
screening of the negative surface charge of the silk particles by the low pH in the vicinity 
of the positive electrode [67]. The e-gels formed in this way have strong adhesive 
properties that are typically absent from other self-assembling silk hydrogels. 
Furthermore, e-gels have outstanding elastic properties and can withstand strains of up to 
2,500%. This contrasts sharply with other physically crosslinked silk hydrogels that rely 
on β-sheet crystals to stabilise the hydrogel network, as those hydrogels tend to be brittle, 
cannot undergo long-range displacements and show low elastic behaviour, with plastic 
deformation typically occurring at strains greater than 10%. Silk e-gels have been 
 27 
proposed for a range of biomedical applications (e.g. adhesives for medical devices, 
sensors, etc.) [66, 67, 78]. However, the need for a DC current could be regarded as a 
limiting factor.   
 
Chemically crosslinked silk hydrogels 
The beauty of silk is its ability to self-assemble under mild processing conditions; thus, 
most studies focus on this character. However, chemically crosslinked silk hydrogels 
have been synthesised using a range of chemistries [60]. For example, using ethylene 
glycol diglycidyl ether [59] or horseradish peroxidase to crosslink the phenol groups of 
tyrosine amino acids [79] to produce silk hydrogels that could withstand a shear strain of 
100% and a compressive strain greater than 70%. The stiffness of these silk hydrogels 
could be fine-tuned to range from 200 to 10,000 Pa by adjusting the silk degumming 
times from 60 to 10 minutes, respectively. These crosslinked silk hydrogels are elastic 
and optically clear over the visible wavelength spectrum [79], unlike physically 
crosslinked gels that typically contain nanocrystalline regions that scatter light. The 
chemically crosslinked silk hydrogels have subsequently been exposed to low-energy 
ultrafast laser pulses to generate complex 3D patterns within the hydrogels that could 
subsequently be populated with cells and monitored [80]. In a similar set of studies, silk 
hydrogels were functionalised with phenol red to endow silk with pH sensing capabilities 
[81].  
 
 However, horseradish peroxidase is immunogenic and complete removal cannot 
be ascertained. Therefore, alternative crosslinkers are being explored. For example, 
 28 
riboflavin (vitamin B2), a photoactive crosslinker, has also been used to generate in situ 
crosslinked silk corneal prostheses aimed at improving visual acuity [82].  
  
 
 
Examples of silk hydrogels for drug and cell delivery 
Silk hydrogels have been studied for a broad range of biomedical applications, including 
cell and drug delivery. Self-assembling silk hydrogels, in particular, are ideally suited for 
these applications (for the reasons detailed above). The following is a critical assessment 
of a few selected examples.  
 
Delivery of small molecular weight anticancer drugs using self-assembling silk hydrogels 
Self-assembling silk hydrogels have been developed for breast cancer focal therapy and 
subjected to pre-clinical testing [39] (Fig. 5). The reverse engineered silk solution was 
exposed to sonication cycles, spiked with doxorubicin and subsequently filled into 
syringes to complete the solutionÐgel transition. In vitro doxorubicin release from silk 
hydrogels over 4 weeks showed no burst release but could be fine-tuned: the fastest 
release was observed for 2% w/v and slowest for 6% w/v silk hydrogels (17% and 27% 
cumulative drug release, respectively) [39]. The strong charge-dependent drug-silk 
interaction appears to be a key driver for the loading and release profiles of doxorubicin 
(a weakly basic drug) [31, 37]. Therefore, increasing the silk content (i.e. from 2 to 6 % 
w/v) significantly slowed the drug release.  
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 The silk secondary structure is also an important factor regulating drug release, as 
a high β-sheet content gives a slower doxorubicin release from model silk films [37]. The 
hydrophobic crystalline domains therefore conceivably may provide a ÒbindingÓ pocket 
for the hydrophobic doxorubicin; however, direct experimental proof for this binding is 
currently lacking. Increasing the degumming time from 20 to 45 minutes results in a 
reduction in the silk molecular weight but has minimal impact on the crystalline domains, 
which appear to be critical for the silkÐdoxorubicin interaction. Not surprisingly, then, 
degumming time did not affect doxorubicin release from silk hydrogels [39].  
 
 All doxorubicin loaded silk hydrogels showed excellent in vitro anticancer 
activity in a human breast cancer relapse model. Therefore, the anticancer activity of 
doxorubicin loaded silk hydrogels was assessed in an orthotopic triple-negative human 
breast cancer model (Fig. 5e). Doxorubicin-loaded silk hydrogels injected next to well-
established breast tumours resulted in complete tumour regression in 2/5 animals and a 
significantly reduced tumour burden and metastasis in all other animals (Fig. 5e). By 
contrast, animals dosed intravenously with the equivalent amount of doxorubicin showed 
only a marginal antitumour effect and significantly greater cardiotoxicity. Thus, drug-
loaded silk hydrogels showed a promising antitumour response in this pre-clinical animal 
model [39] and outperformed a PEG-heparin hydrogel system assessed in a parallel study 
using the same cancer model and doxorubicin loading [83]. A similar set of studies 
examined self-assembling silk hydrogels loaded with vincristine and tested in an 
orthotopic neuroblastoma mouse model [38]. This focal therapy was also able to improve 
survival; these hydrogels performed similarly to drug-loaded silk foams, which 
 30 
significantly changed vincristine pharmacokinetics. Focal therapy resulted in very high 
drug tumour concentrations (up to 1,000-fold greater than for ivÐdosed animals) and 
increased plasma concentrations when compared to the ivÐdosed vincristine [38].  
 
Delivery of biologics using self-assembling silk hydrogels 
Physically crosslinked silk hydrogels are well suited for injection because they 
show shear thinning. Furthermore, silk also has a remarkable ability to stabilise 
therapeutic proteins (detailed above, reviewed in [84, 85]). Thus, silk hydrogels not only 
deliver a payload, but they also protect their cargo. Self-assembling silk hydrogels have 
been examined for their ability to deliver bevacizumab (a monoclonal antibody of anti-
vascular endothelial growth factor) for the treatment of age-related macular degeneration 
[49]. Silk cocoons were degummed (no details provided) and reverse engineered. 
Bevacizumab was added to the silk solution at a standard dose (1.25 mg/50 µl of 2% w/v 
silk solution) and a high dose (5 mg/50 µl of 2% w/v silk solution) and subsequently 
sonicated to induce gel formation. The sonication was performed at a sufficiently low 
energy to minimise sample heating and to conserve biological activity of bevacizumab. In 
vitro release studies showed an initial burst release of the drug during the first 10 days for 
all samples. The highest initial drug release occurred with the commercial preparation, 
but this release subsequently fell below the level of detection within 33 days. By contrast, 
drug release from the silk hydrogels was more sustained over 90 days, with bevacizumab 
levels higher for the high dose samples than for the standard dose ones [49].  
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Next, drug release was assessed in healthy rabbits, which underwent intravitreal 
injection with 50 µl of either the commercial preparation, the standard loaded or the high 
loaded silk hydrogel preparation [49]. Tracking bevacizumab levels in the blood plasma 
revealed similar in vivo kinetics to those observed in vitro. Drug levels in the vitreous and 
aqueous humour at extended times were substantially higher for animals dosed with both 
silk hydrogel preparations than with the commercial preparation. Pharmacokinetic 
parameters indicated similar relative bioavailability of the commercial and silk hydrogel 
bevacizumab (i.e. area under the curve 3,300 and 2,520 µg/ml × day), but the terminal 
half-life for both silk hydrogel preparations was 2 to 3-fold higher. Optical assessment of 
the silk hydrogels indicated a 30 to 75% volume reduction, which was interpreted as silk 
biodegradation (but could also be due to hydrogel shrinkage, or a combination of both). 
The intravitreal route of administration remains a major challenge because the hydrogel 
sits in the vitreous [49] and obstructs the optical light path, thereby obscuring vision. 
Furthermore, the observed burst release for the silk hydrogels requires more optimisation, 
but similar results have been reported for other monoclonal antibodies and silk delivery 
systems [86]. 
 
(Stem) cell delivery using self-assembling silk hydrogels 
The excellent material properties of silk have supported the development of various 
hydrogel systems for soft and hard tissue engineering applications (reviewed in [87, 88]). 
For example, pancreatic islet transplantation is challenging because of the functional 
decline and reduced viability of the islets during the peritransplantation period. 
Therefore, self-assembling silk hydrogels (1.2% w/v) were assessed as a potential 
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delivery system [47]. Silk was vortexed, and prior to the completion of the solutionÐgel 
transition, the silk preparation was loaded with cells. Three treatment groups were 
assessed: (i) pelleted pancreatic islets (i.e. no delivery matrix), (ii) pancreatic islets 
embedded in silk and (iii) pancreatic islets with mesenchymal stem cells (MSCs) 
embedded in silk. Following the completion of the solutionÐgel transition, diabetic mice 
were surgically implanted with a graft in the epidermal fat pad, and the grafts were 
subjected to functional tests (i.e. blood glucose monitoring and intraperitoneal glucose 
tolerance test).  
 
 Silk hydrogels containing marginal pancreatic islets grafts performed best and 
were able to control blood glucose within 4 days, whereas pelleted pancreatic islets 
required 15 days and silk hydrogels loaded with both pancreatic islets and MSCs  
required 9 days. The silk hydrogel was noted to induce expression of vascular endothelial 
growth factor (VEGF), and VEGF, in turn, could improve graft survival and function. 
The transplanted MSCs further supported graft function via trophic and angiogenic factor 
expression, as demonstrated by minimal islet grafts that were able to control glucose 
levels in 3 out of 4 mice. However, the minimal islet grafts were not able to control 
glucose when transplanted only with silk or as pelleted pancreatic islets only (Fig. 6) 
[47].  
 
Although MSCs supported islet function, they also resulted in an unintended 
outcome: at the end of the study, the transplanted MSCs (day 42) had formed new 
ossicles [47] indicating that the silk hydrogel matrix was not able to maintain MSCs in a 
 33 
multipotent state but instead had inadvertently supported osteogenic differentiation. 
Therefore, silk hydrogels require fine-tuning to direct MSC lineage commitment, and 
chemical modification of silk hydrogels [89], the inclusion of growth factors and the 
adjustment of physical properties [90] will be key parameters that will control MSC 
behaviour.  
 
Note that silk hydrogels have been used for bone tissue engineering applications 
(reviewed in [91]), but the hydrogels tend to be brittle. Consequently, the inclusion of silk 
fibres has emerged as a valuable strategy [92] to improve mechanical strength while 
serving as a physical cue for MSC differentiation. 
 
Future Perspective 
Printing silk hydrogels 
A range of printing technologies has been used in combination with silk to print: (i) 
liquid silk [93], (ii) pre-gelled (recombinant) silks [94], (iii) silk-based bioinks [95] and 
(iv) chemically modified silks [96]. Stable silk structures are created using both physical 
and chemical crosslinking. For example, reverse engineered silk has been used as a 
carrier material and matrix for a broad range of applications, including sensing, 
therapeutics and regenerative medicine [93]. The liquid silk was doped with the active 
component (e.g. model drugs, sensors, nanoparticles) and subsequently printed onto a 
range of substrates (e.g. paper, petri dishes, gloves, etc.). The deposited silk was allowed 
to self-assemble on the respective surface and assessed for functionality: gold 
nanoparticle-doped printed silk arrays could be selectively heated, bone morphogenic 
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protein doped silk could differentiate MSCs into osteoblasts and IgG functionalised silk 
sensors on gloves could detect bacterial contamination. While these applications 
demonstrate the versatility of silk, it remains to be seen if a similar diversity can also be 
achieved with silk hydrogels (note that actually no silk hydrogel was formed in this study 
[93]). The suitability of self-assembled silk hydrogels, as well as chemically cross linked 
polymeric networks, for three dimensional printing has been demonstrated with reverse 
engineered silk [97]. For the self-assembling systems, silk was sonicated and then the 
cells were added to the liquid silk, which was allowed to complete the solutionÐgel 
transition and subsequently extruded under pressure. The resulting three-dimensional 
constructs could be readily manufactured to a 500 µm resolution and supported cell 
viability [97].  
 
 Others have developed liquid bioinks that self-assemble after printing. Here, 
anionic polyglutamic acid and cationic polylysine modified silks were synthesised, the 
pH adjusted to 5.5 and the material sequentially printed to generate silk arrays. Through 
additive manufacturing, these striated silk arrays were populated with E. coli cells [96]. 
In other studies, mixtures of silk, gelatine and glycerol have been optimised and 
subsequently used to print complex three-dimensional structures. Here, the gelatine 
served as a bulking material and a thermoresponsive switch. The mixture was melted and 
extruded at 37¡C to achieve Newtonian like flow characteristics and deposited on a 
surface at 20¡C to 25¡C. The structures were stable but required immersion in a glycerol 
bath to induce β-sheets to render the printed constructs water insoluble [95]. These types 
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of studies are promising, but require further work because the glycerol immersion bath is 
incompatible with the in situ printing of cells.  
 
 Chemical crosslinking has also been piloted; for example, combining silk with 
alginate and horseradish peroxidase allowed the development of a two-step cross-linking 
protocol [98]. First, the mixture was printed into a CaCl2 bath to induce ionic cross 
linking of alginate; the alginate network immobilised the silk and horseradish peroxidase. 
Next, addition of hydrogen peroxide catalysed the chemical cross-linking of tyrosine 
residues within the silk sequence. Addition of sodium citrate dismantled the ionic 
crosslinks of the alginate and subsequent washing removed the sacrificial alginate from 
the system [98].  
 
 Overall, tremendous opportunities exist for the exploitation of silk for printing 
applications, as demonstrated by the developments reported over the past 5 years.  
 
Summary 
This review provides a detailed background of silk and its many facets, and it summarises 
recent developments in the production and use of self-assembling silk hydrogels. In it, we 
have addressed common pitfalls and misconceptions while identifying emerging 
opportunities. Of course, silk has its limits, and we must recognise these and build on 
new insights.  
 
Executive Summary 
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Silk 
¥ Numerous different silks exist in nature which are produced by many different 
animals, including, but not limited to, spiders and silkworms. 
¥ B. mori is the domesticated silkworm which is used commercially to produce silk 
on an industrial scale typically for the textile industry. 
¥ B. mori silk is approved for human clinical use for load bearing applications in its 
fibre format (i.e. sutures and surgical mesh) and as a wound dressing (i.e. a silk 
sponge attached to a silicon film, approved in China only). 
 
Biocompatibility and biodegradation 
¥ Silk is susceptible to proteolysis leading to silk biodegradation. The rate and 
extend is dependent on many factors including the silk format, secondary 
structure and processing history as well as the implantation site in vivo. 
¥ Silk is demonstrating excellent biocompatibility across a range of applications. 
This trend appears to be robust from mice to man.  
 
Silk hydrogels 
¥ Many hydrogels exploit the endogenous self-assembly of silk. The underlying 
principle is typically based on physical crosslinking due to exposure of 
crystallisable silk sequences. 
¥ Chemical cross linking of silk yields hydrogels which are significantly more 
elastic than those formed by physical cross linking. Due to the absence of 
 37 
nanocrystallites, chemical cross linked hydrogels are optical transparent to visible 
light. 
¥ Silk hydrogels are emerging as promising substrates for drug and cell delivery 
applications, especially those systems exploiting the self-assembly behaviour of 
silk. 
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Figure 1.  Silk structure of Bombyx mori. (A) Solution conformation of silk. 
Hydrophobicity pattern of the heavy chain with possible chain folding and micelle 
assembly of silk in water. (B) Two dimensional silk schematic. (C) Primary structure of 
the silk heavy chain. R01 to R12 and A01 to A11 represent the arrangement of 12 
repetitive and 11 amorphous regions, respectively. The approximate amino acid sequence 
of the R10 is shown by combination of sequences of i, ii and iii. (Panel A adapted with 
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permission from [19]. Panel B adapted with permission from [9] and panel C adapted 
with permission from [16], Copyright American Chemical Society). 
 
 
Figure 2. Reverse engineering of silk cocoons. Silk cocoons, degummed silk fibres and 
fully reverse engineered liquid silk.  
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Figure 3. The silk structure and cleavage site by proteolytic enzymes (reprinted with 
permission from [9]). 
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Figure 4. The structural characteristics of silk hydrogels. Scanning electron micrographs 
of different hydrogel morphologies derived from silk solution (i) of low and (ii) high 
concentration and (iii) silk e-gel. Note that the low and high silk concentration hydrogels 
(i.e. images i and ii) were allowed to self-assemble over several days whereas e-gels are 
formed within minutes. Reprinted with permission from [70]. Copyright American 
Chemical Society. 
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Figure 5. Self-assembling silk hydrogels for focal breast cancer focal therapy. (A) Impact 
of processing parameters on the solution-gel kinetics of silk (the open plot symbols 20 
minute degummed silk, closed plot symbols 45 minutes degummed silk). (B) Silk 
hydrogels show no swelling during the solution-gel transition. (C) Doxorubicin release 
from different silk hydrogels. (D) Injectability of drug loaded silk hydrogels. (E) 
Response of MDA-MB-231 human breast cancer xenografts to treatment. Reproduced 
with permission from [39]. 
 
 
 
Figure 6. Performance of minimal pancreatic islets transplants in diabetic mice. (A) The 
treatment groups were (i) pelleted pancreatic islets (open circles), (ii) pancreatic islets 
delivered with a silk hydrogel (open squares) and (iii) pancreatic islets co-transplanted 
with mesenchymal stem cells and delivered with a silk hydrogel (closed squares). Only 
treatment group (iii) was able to control glucose levels and eliminated diabetes in 80% of 
mice (solid line). Reproduced with permission from [47].   
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